Refine by
Neuropathies Articles & Analysis
66 news found
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
Epalrestat Epalrestat is used to treat diabetic neuropathy, a condition that affects millions of people worldwide. By providing high-quality epalrestat as active pharmaceutical ingredients, Alfa Chemistry is supporting the development of better treatments for this condition and helping to improve the quality of life for people living with diabetes. ...
While most studies focused on Gd presence in brain, the current study evaluated the skin of animal foot pads for Gd presence and neuro-histological changes after multiple GBCA exposure. No signs for small fiber neuropathy in the skin of the foot pads were observed. In addition, Bayer’s Radiology team will present the launch of the MEDRADTM MRXperion MR Multi-Patient ...
ByBayer AG
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate (OUD), and cocaine addiction, alcoholism (AUD), post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral ...
Diabetic patients with Diabetic Peripheral Neuropathy will be recruited for Phase I trial. One of other non-clinical stage assets, PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and shows no binding to EGFR wild type. ...
However, HSCT does not correct the peripheral neuropathy that is progressive as the patient grows, leading to loss of gross motor skills and eventually death. ...
Soliz will develop a commercial prototype and seek FDA approval of i-RxTherm, his device for detecting DPN (diabetic peripheral neuropathy or diabetic foot). ...
Healthcare providers may suggest this procedure for those with a variety of afflictions including reflex sympathetic dystrophy, diabetic neuropathy, ulcers, or frostbite. Like the other procedures mentioned, you will lie on your stomach and receive sedation medicine to prepare yourself for the injection. ...
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, ...
25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC’s sponsors and the HTID health innovation ecosystem. The HealthTech Innovation Days (HTID®) event, organized by the HealthTech For Care (HTFC) endowment fund, is launching ...
FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease, as well as to drastically improve lifespan in animal models of the disease. ...
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to ...
VisionQuest founder and CEO Peter Soliz (PhD) presented the poster “Detecting diabetic peripheral neuropathy utilizing thermoregulation biomarkers of the plantar foot” at the American Diabetes Association’s 82nd Scientific Sessions last Sunday in New Orleans. ...
Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 1/2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, which is being developed under a worldwide collaboration with Roche ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical compound for the potential treatment of a range of inflammatatory, neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in ...
How much do you know about the development of your favorite products? What about the devices you encounter at your doctor’s office? So much of the work that goes into every single thing we use remains unseen by the user or consumer, from concept development to design to ...
Our Foot/Ankle BioWrap is designed to treat pain throughout the entire foot and ankle, so we are very excited about the opportunity to help patients that suffer from painful diabetic neuropathy,” said Bradford Siff, Founder & President. “We help manage severe pain and reduce opioid consumption for over 10,000 veterans per year in over 190 VA Hospitals and CBOCs ...
Patients suffering from low back pain, sciatica, and neuropathy caused by those disc conditions have a profound success rate in resolving their symptoms when treated on the ...
Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 1/2a development for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a ...